| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014908078 |
| P356 | DOI | 10.1186/1471-2407-13-76 |
| P932 | PMC publication ID | 3579688 |
| P698 | PubMed publication ID | 23406262 |
| P5875 | ResearchGate publication ID | 235619435 |
| P50 | author | Holger Jens Schünemann | Q1237005 |
| Jean Pierre Hachem | Q89848663 | ||
| Nawman Labedi | Q117264373 | ||
| Victor F Kairouz | Q117264390 | ||
| Elie A Akl | Q29838958 | ||
| Gabriel Rada | Q40491677 | ||
| P2860 | cites work | Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review | Q21090146 |
| Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others | Q21563421 | ||
| Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer | Q24235023 | ||
| Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation | Q24235112 | ||
| Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer | Q24235193 | ||
| Anticoagulation for patients with cancer and central venous catheters | Q24235260 | ||
| Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation | Q24236595 | ||
| Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer | Q24236620 | ||
| CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials | Q52904746 | ||
| The clinical and radiological characteristics and evolution of incidentally diagnosed pulmonary thromboembolism | Q53417613 | ||
| [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer] | Q77622732 | ||
| Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Q79825413 | ||
| Pharmaceutical industry sponsorship and research outcome and quality: systematic review | Q24673248 | ||
| GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias) | Q29619791 | ||
| Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed | Q33655835 | ||
| Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know | Q33675061 | ||
| Citation indexes do not reflect methodological quality in lung cancer randomised trials | Q35110208 | ||
| Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group | Q35113260 | ||
| Methodological quality and reporting of ethical requirements in phase III cancer trials | Q35429600 | ||
| Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752541 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Discordance between reported intention-to-treat and per protocol analyses | Q36851217 | ||
| Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies | Q37829868 | ||
| Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer | Q37863724 | ||
| Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid | Q37971411 | ||
| Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis | Q38698807 | ||
| Evaluation of the quality of radiotherapy randomized trials for painful bone metastases | Q40437465 | ||
| Maintenance chemotherapy for small cell lung cancer: a critical review of the literature | Q40861064 | ||
| Methodologic issues in effectiveness research on palliative cancer care: a systematic review | Q40898443 | ||
| Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience | Q42703932 | ||
| Quality of randomized controlled trials reporting in the primary treatment of brain tumors | Q44545965 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulant | Q215118 |
| neoplasm | Q1216998 | ||
| randomized controlled trial | Q1436668 | ||
| research design | Q1438035 | ||
| venous thrombosis | Q2751330 | ||
| anticoagulation | Q63279445 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 76 | |
| P577 | publication date | 2013-02-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer | |
| P478 | volume | 13 |
Search more.